Late-onset Epstein-Barr virus-related disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation is associated with impaired early recovery of T and B lymphocytes

Clinical Transplantation

Volumn 29, Issue 10, 2015, Pages 904-910

  Liu, Jiangying ^a   Yan, Chenhua ^a   Zhang, Chunli ^a   Xu, Lanping ^a   Liu, Yanrong ^a   Huang, Xiaojun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Acute leukemia; EBV related disease; Epstein Barr virus; Hematopoietic stem cell transplantation; Immune reconstitution

Indexed keywords

CD19 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN;

ACUTE LEUKEMIA; ADAPTIVE IMMUNITY; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS INFECTION; EPSTEIN BARR VIRUS RELATED DISEASE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; NEUTROPHIL; PRIORITY JOURNAL; T LYMPHOCYTE; ADOLESCENT; ADULT; ADVERSE EFFECTS; CHILD; FEMALE; FOLLOW UP; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADAPTIVE IMMUNITY; ADOLESCENT; ADULT; B-LYMPHOCYTES; CHILD; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942983935     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12593     Document Type: Article

References (27)

1. Huang XJ, Zhu HH, Chang YJ et al. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood 2012: 119: 5584.
2. Grosso D, Flomenberg N. A two-step approach to allogeneic haploidentical hematopoietic stem cell transplantation. Semin Oncol 2012: 39: 694.
3. Wang Y, Liu DH, Liu KY et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer 2013: 119: 978.
4. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004: 350: 1328.
5. Styczynski J, Reusser P, Einsele H et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009: 43: 757.
6. Ocheni S, Kroeger N, Zabelina T et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 2008: 43: 181.
7. Xuan L, Jiang X, Sun J et al. Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation. Transplantation 2013: 96: 560.
8. van Esser JW, Niesters HG, van der Holt B et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002: 99: 4364.
9. Bosch M, Khan FM, Storek J. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol 2012: 19: 324.
10. Cavazzana-Calvo M, Andr'e-Schmutz I, Dal Cortivo L, Neven B, Hacein-Bey-Abina S, Fischeret A. Immune reconstitution after hematopoietic stem cell transplantation: obstacles and anticipated progress. Curr Opin Immunol 2009: 21: 544.
11. Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010: 13: 3861.
12. Chang YJ, Zhao XY, Huo MR et al. Immune reconstitution following unmanipulated HLA-mismatched/haploidentical transplantation compared with HLA-identical sibling transplantation. J Clin Immunol 2012: 32: 268.
13. Montero A, Savani BN, Shenoy A et al. T-cell depleted peripheral blood stem cell allo-transplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome. Biol Blood Marrow Transplant 2006: 12: 1318.
14. Savani BN, Mielke S, Rezvani K et al. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007a: 13: 1216.
15. Mackall CL, Granger L, Sheard MA, Cepeda R, Gress RE. T-cell regeneration after bone marrow transplantation: differential CD45 isoform expression on thymic-derived versus thymic-independent progeny. Blood 1993: 82: 2585.
16. Berger M, Figari O, Bruno B et al. Lymphocyte subsets recovery following allogeneic bone marrow transplantation (BMT): CD4 + T-cell count and transplant-related mortality. Bone Marrow Transplant 2008: 41: 55.
17. Mackall C, Fry T, Gress R, Peggs K, Storek J, Toubert A. Background to hematopoietic cell transplantation, including post transplant immune recovery. Bone Marrow Transplant 2009: 44: 457.
18. Gasser O, Bihl FK, Wolbers M et al. HIV patients developing primary CNS lymphoma lack EBV-specific CD4 + T cell function irrespective of absolute CD4 + T cell counts. PLoS Med 2007: 4: e96.
19. Clement LT. Isoforms of the CD45 common leukocyte antigen family: markers for human T-cell differentiation. J Clin Immunol 1992: 12: 1.
20. Richards D, Chapman MD, Sasama J, Lee TH, Kemeny DM. Immune memory in CD4 + CD45RA+ T-cells. Immunology 1997: 91: 331.
21. Kim HO, Oh HJ, Lee JW et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation in children: a single institution study of 59 patients. Korean J Pediatr 2013: 56: 26.
22. Rutella S, Locatelli F. Strategies to harness immunity against infectious pathogens after haploidentical stem cell transplantation. Am J Transl Res 2011: 3: 404.
23. Meerbach A, Wutzler P, Häfer R, Zintl F, Gruhn B. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post transplant lymphoproliferative disease. J Med Virol 2008: 80: 441.
24. Meijer E, Cornelissen JJ. Epstein-Barr virus associated lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Curr Opin Hematol 2008: 15: 576.
25. Hoegh-Petersen M, Goodyear D, Geddes MN et al. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts. Bone Marrow Transplant 2011: 46: 1104.
26. Hoegh-Petersen M, Sy S, Ugarte-Torres A et al. High Epstein-Barr virus-specific T-cell counts are associated with near zero likelihood of acute myeloid leukemia relapse after hematopoietic cell transplantation. Leukemia 2012: 26: 359.
27. Forcina A, Noviello M, Carbone MR, Bonini C, Bondanza A. Predicting the clinical outcome of allogeneic hematopoietic stem cell transplantation: the long and winding road toward validated immune biomarkers. Front Immunol 2013: 4: 71.